Novo Nordisk Aktie
WKN: 866931 / ISIN: US6701002056
26.10.2024 17:30:00
|
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care.The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic, Wegovy, Rybelsus, and Saxenda. The main compound that Ozempic, Wegovy, and Rybelsus share is called semaglutide.However, what sets Rybelsus apart from its sibling treatments is that it is an oral pill, whereas Ozempic and Wegovy are administered via injection.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novo Nordisk (spons. ADRs)mehr Nachrichten
Analysen zu Novo Nordisk (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Novo Nordisk (spons. ADRs) | 57,80 | -5,86% |
|